United States · Platforms & data · Morningstar
Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026
Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for…
Read the full article on Morningstar Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)
-logo-1200x675.png?v=20261007110104){kind=logo}
